Stocks TEVA Financial statements
Financial statementsTEVA PHARMACEUTICAL INDUSTRIES LTD financial statements
Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data TEVA PHARMACEUTICAL INDUSTRIES LTD files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21,903 | 22,385 | 18,271 | 16,887 | 16,659 | 15,878 | 14,925 | 15,846 | 16,544 | 17,258 |
| Cost of revenue | 10,250 | 11,237 | 9,975 | 9,351 | 8,933 | 8,284 | 7,952 | 8,200 | 8,481 | 8,320 |
| Gross profit | 11,653 | 10,615 | 8,296 | 7,537 | 7,726 | 7,594 | 6,973 | 7,645 | 8,064 | 8,938 |
| Research and development | 422 | 175 | 114 | 1,010 | 997 | 967 | 98 | 953 | 998 | 1,013 |
| Selling and marketing | 3,583 | 3,395 | 2,916 | 2,614 | 2,498 | 2,429 | 2,265 | 2,336 | 2,541 | 2,686 |
| General and administrative | 1,390 | 1,451 | 1,298 | 1,192 | 1,173 | 1,099 | 1,180 | 1,162 | 1,161 | 1,287 |
| Operating income | 2,154 | -17,484 | -1,637 | -443 | -3,572 | 1,716 | -2,197 | 433 | -303 | 2,157 |
| Interest expense | 546 | 875 | 920 | 822 | 901 | 891 | 930 | 1,029 | 1,002 | 916 |
| Other non-operating income | -1,330 | -895 | -959 | -822 | -834 | -1,058 | -966 | -1,057 | -981 | -934 |
| Pre-tax income | 824 | -18,379 | -2,596 | -1,265 | -4,406 | 658 | -3,163 | -624 | -1,284 | 1,223 |
| Income tax | 521 | -1,933 | -195 | -278 | -168 | 211 | -643 | -7 | 676 | -180 |
| Net income to minority interests | -18 | -184 | -322 | -2 | -109 | 39 | -53 | -56 | -320 | 7 |
| Net income | 329 | -16,265 | -2,150 | -999 | -3,990 | 417 | -2,446 | -559 | -1,639 | 1,410 |
| EBITDA | 3,678 | -15,372 | 205 | 1,279 | -2,015 | 3,046 | -889 | 1,586 | 756 | 3,159 |
| EPS, basic | 0.07 | -16.26 | -2.35 | -0.91 | -3.64 | 0.38 | -2.20 | -0.50 | -1.45 | 1.23 |
| EPS, diluted | 0.07 | -16.26 | -2.35 | -0.91 | -3.64 | 0.38 | -2.20 | -0.50 | -1.45 | 1.21 |
| Shares, basic (weighted) | 0 | 1,016 | 1,021 | 1,091 | 1,095 | 1,102 | 1,110 | 1,119 | 1,131 | 1,145 |
| Shares, diluted (weighted) | 0 | 1,016 | 1,021 | 1,091 | 1,095 | 1,107 | 1,110 | 1,119 | 1,131 | 1,163 |
| Dividend per share | 1.36 | 0.85 | 0.00 | 0.00 |
Balance sheet
| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 988 | 963 | 1,782 | 1,975 | 2,177 | 2,165 | 2,801 | 3,226 | 3,300 | 3,556 |
| Receivables | 7,523 | 7,128 | 5,822 | 5,676 | 4,581 | 4,529 | 3,696 | 3,408 | 3,059 | 3,709 |
| Inventory | 4,954 | 4,924 | 4,731 | 4,422 | 4,403 | 3,818 | 3,833 | 4,021 | 3,007 | 3,179 |
| Other current assets | 701 | 468 | 434 | 710 | 965 | 549 | 504 | 409 | 539 | |
| Total current assets | 17,228 | 15,382 | 13,794 | 13,464 | 13,005 | 12,573 | 12,051 | 12,485 | 12,552 | 13,946 |
| Property, plant and equipment | 8,073 | 7,673 | 6,868 | 6,436 | 6,296 | 5,982 | 5,739 | 5,750 | 4,581 | 4,080 |
| Lease right-of-use assets | 514 | 559 | 495 | 419 | 397 | 367 | 345 | |||
| Goodwill | 44,409 | 28,414 | 24,917 | 24,846 | 20,624 | 17,633 | 17,177 | 17,177 | 16,000 | 16,000 |
| Intangible assets | 21,487 | 17,640 | 14,005 | 11,232 | 8,923 | 7,466 | 6,270 | 5,387 | 4,418 | 3,781 |
| Other non-current assets | 1,235 | 932 | 731 | 591 | 538 | 515 | 441 | 470 | 462 | 405 |
| Total assets | 93,057 | 70,615 | 60,683 | 57,470 | 50,640 | 47,666 | 44,011 | 43,479 | 39,326 | 40,748 |
| Accounts payable | 2,157 | 2,069 | 1,853 | 1,718 | 1,756 | 1,686 | 1,887 | 108 | 158 | 225 |
| Accrued liabilities | 549 | 870 | 693 | 685 | 23 | 566 | 611 | 624 | 739 | |
| Short-term debt | 3,276 | 3,646 | 2,216 | 2,345 | 3,188 | 1,426 | 2,109 | 1,672 | 1,781 | 1,820 |
| Total current liabilities | 18,488 | 17,921 | 14,322 | 13,674 | 13,164 | 11,027 | 11,469 | 12,247 | 12,796 | 13,456 |
| Lease liabilities | 435 | 479 | 416 | 349 | 320 | 296 | 288 | |||
| Other non-current liabilities | 1,639 | 1,843 | 1,727 | 2,640 | 2,240 | 2,578 | 3,945 | 4,019 | 4,028 | 3,808 |
| Total liabilities | 58,064 | 51,870 | 44,889 | 42,407 | 39,579 | 36,422 | 35,413 | 35,353 | 33,606 | 32,834 |
| Total debt | 32,524 | 28,829 | 1,700 | 1,831 | 2,674 | 1,403 | 2,086 | 1,649 | 1,758 | 1,798 |
| Paid-in capital | 23,409 | 23,479 | 27,210 | 27,312 | 27,443 | 27,561 | 27,688 | 27,807 | 27,764 | 28,133 |
| Retained earnings | 13,607 | -3,803 | -5,958 | -6,956 | -10,946 | -10,529 | -12,975 | -13,534 | -15,173 | -13,762 |
| Treasury stock | -4,194 | -4,149 | -4,142 | -4,128 | -4,128 | -4,128 | -4,128 | -4,128 | -4,128 | -4,128 |
| Other comprehensive income | -3,159 | -1,853 | -2,459 | -2,312 | -2,399 | -2,683 | -2,838 | -2,697 | -3,148 | -2,391 |
| Shareholders' equity | 33,337 | 17,359 | 14,707 | 13,972 | 10,026 | 10,278 | 7,804 | 7,506 | 5,373 | 7,910 |
| Minority interests | 1,656 | 1,386 | 1,087 | 1,091 | 1,035 | 966 | 794 | 620 | 7 | 4 |
| Total equity | 34,993 | 18,745 | 15,794 | 15,063 | 11,061 | 11,244 | 8,598 | 8,126 | 5,380 | 7,914 |
| Total liabilities and equity | 93,057 | 70,615 | 60,683 | 57,470 | 50,640 | 47,666 | 44,011 | 43,479 | 39,326 | 40,748 |
Cash flow statement
| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income | 311 | -16,449 | -2,472 | -1,000 | -4,099 | 456 | -2,499 | -615 | -1,959 | 1,418 |
| Depreciation and amortization | 1,524 | 2,112 | 1,842 | 1,722 | 1,557 | 1,330 | 1,308 | 1,153 | 1,059 | 1,002 |
| Stock-based compensation | 124 | 133 | 155 | 119 | 129 | 119 | 124 | 121 | 123 | 157 |
| Deferred income tax | 40 | -2,306 | -895 | -1,163 | -350 | -59 | -1,073 | -340 | -418 | |
| Change in inventory | -370 | -199 | -26 | -271 | -41 | -380 | 163 | 147 | -166 | -152 |
| Cash from operations | 3,890 | 2,225 | 2,446 | 748 | 1,216 | 798 | 1,590 | 1,368 | 1,247 | 1,649 |
| Capital expenditures | -901 | -874 | -651 | -525 | -578 | -562 | -548 | -526 | -498 | -501 |
| Acquisitions | -36,148 | 43 | 0 | 0 | -7 | 0 | -15 | 0 | ||
| Sales and maturities of investments | 2,002 | 3,477 | 890 | 2 | 12 | 172 | 4 | 0 | 40 | 42 |
| Cash from investing | -34,405 | 3,446 | 1,866 | 1,355 | 863 | 1,523 | 656 | 968 | 792 | 737 |
| Debt repaid | -999 | -3,300 | -7,446 | -3,944 | -1,871 | -6,649 | -1,369 | -4,152 | -1,641 | -4,112 |
| Stock issued | 329 | 0 | 19 | 47 | ||||||
| Share buybacks | 0 | 0 | ||||||||
| Dividends paid | -1,303 | -901 | -12 | |||||||
| Cash from financing | 25,217 | -5,750 | -3,351 | -1,926 | -1,885 | -2,172 | -1,487 | -1,913 | -1,791 | -2,151 |
| Exchange rate effect | -660 | 54 | -142 | 16 | 8 | -128 | -123 | -30 | -174 | 21 |
| Net change in cash | -5,958 | -25 | 819 | 193 | 202 | 21 | 636 | 393 | 74 | 256 |
| Free cash flow | 2,989 | 1,351 | 1,795 | 223 | 638 | 236 | 1,042 | 842 | 749 | 1,148 |
| Interest paid | 290 | 795 | 815 | 840 | 846 | 913 | 948 | 1,078 | 1,004 | 950 |
| Income taxes paid | 341 | 106 | 420 | 552 | 709 | 495 | 543 | 298 | 471 |
Key metrics
Profitability
| Metric | Value | How it is calculated |
|---|---|---|
| Gross margin | 64.4% | Gross profit / revenue. |
| Operating margin | 11.4% | Operating income / revenue. |
| EBITDA margin | 18.4% | EBITDA (operating income + depreciation and amortization) / revenue. |
| Pre-tax margin | 5.0% | Pre-tax income / revenue. |
| Net margin | 5.0% | Net income / revenue. |
| FCF margin | 9.6% | Free cash flow (cash from operations - capital expenditures) / revenue. |
| Operating cash flow margin | 13.5% | Cash from operations / revenue. |
| Effective tax rate | 1.7% | Income tax / pre-tax income, when pre-tax income is positive. |
| Return on equity (ROE) | 9.1% | Net income / average shareholders' equity (opening and closing). Not shown when equity is negative. |
| Return on assets (ROA) | 1.8% | Net income / average total assets. |
| Return on invested capital (ROIC) | 18.3% | Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%. |
| R&D / revenue | 12.2% | Research and development expense / revenue. |
| Stock-based pay / revenue | 1.2% | Stock-based compensation (from the cash flow statement) / revenue. |
| Capex / revenue | 3.9% | Capital expenditures / revenue. |
| D&A / revenue | 7.0% | Depreciation and amortization / revenue. |
Growth
| Metric | Value | How it is calculated |
|---|---|---|
| Revenue growth, 1y | 4.3% | Revenue vs the same period a year earlier. Only from a positive base. |
| Revenue CAGR, 3y | 5.0% | Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive. |
| Revenue CAGR, 5y | 0.7% | Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Gross profit growth, 1y | 10.8% | Gross profit vs the same period a year earlier. Only from a positive base. |
| Gross profit CAGR, 3y | 8.6% | Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive. |
| Gross profit CAGR, 5y | 3.0% | Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| EBITDA growth, 1y | 317.9% | EBITDA vs the same period a year earlier. Only from a positive base. |
| Operating cash flow growth, 1y | 32.2% | Operating cash flow vs the same period a year earlier. Only from a positive base. |
| Operating cash flow CAGR, 3y | 1.2% | Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive. |
| Operating cash flow CAGR, 5y | 6.3% | Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Free cash flow growth, 1y | 53.3% | Free cash flow vs the same period a year earlier. Only from a positive base. |
| Free cash flow CAGR, 3y | 3.3% | Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive. |
| Free cash flow CAGR, 5y | 12.5% | Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Book value growth, 1y | 47.2% | Book value vs the same period a year earlier. Only from a positive base. |
| Book value CAGR, 3y | 0.5% | Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive. |
| Book value CAGR, 5y | -4.6% | Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Total assets growth, 1y | 3.6% | Total assets vs the same period a year earlier. Only from a positive base. |
| Total assets CAGR, 3y | -2.5% | Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive. |
| Total assets CAGR, 5y | -4.3% | Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Share count change, 1y | 2.8% | Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution. |
| Share count change per year, 3y | 1.6% | Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution. |
| Share count change per year, 5y | 1.2% | Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution. |
Balance sheet health
| Metric | Value | How it is calculated |
|---|---|---|
| Current ratio | 0.88x | Current assets / current liabilities. |
| Quick ratio | 0.46x | (Cash + short-term investments + receivables) / current liabilities. |
| Cash ratio | 0.23x | (Cash + short-term investments) / current liabilities. |
| Debt / equity | 0.58x | Total debt / shareholders' equity. Not shown when equity is negative. |
| Debt / assets | 11.3% | Total debt / total assets. |
| Liabilities / assets | 80.5% | Total liabilities / total assets. |
| Net debt | $845.0M | Total debt - cash - short-term investments. Negative means more cash than debt. |
| Net debt / EBITDA | 0.33x | Net debt / EBITDA (twelve months), when EBITDA is positive. |
| Working capital | -$1.89B | Current assets - current liabilities. |
| Goodwill and intangibles / assets | 48.4% | (Goodwill + intangible assets) / total assets. |
| Tangible book value | -$11.53B | Shareholders' equity - goodwill - intangible assets. |
Efficiency
| Metric | Value | How it is calculated |
|---|---|---|
| Asset turnover | 0.35x | Revenue / average total assets. |
| Fixed asset turnover | 3.59x | Revenue / average property, plant and equipment. |
| Inventory turnover | 2.56x | Cost of revenue / average inventory. |
| Days inventory | 143 days | 365 x average inventory / cost of revenue. |
| Receivables turnover | 4.04x | Revenue / average receivables. |
| Days sales outstanding | 90 days | 365 x average receivables / revenue. |
| Days payables | 121 days | 365 x average accounts payable / cost of revenue. |
| Cash conversion cycle | 113 days | Days inventory + days sales outstanding - days payables. |
| FCF conversion | 190.9% | Free cash flow / net income, when net income is positive. |
| Capex / operating cash flow | 29.0% | Capital expenditures / cash from operations, when that is positive. |
Per share
| Metric | Value | How it is calculated |
|---|---|---|
| EPS, diluted | $0.61 | Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS. |
| Revenue per share | $12.11 | Revenue / diluted weighted shares. |
| FCF per share | $1.16 | Free cash flow / diluted weighted shares. |
| Operating cash flow per share | $1.63 | Cash from operations / diluted weighted shares. |
| Book value per share | $6.65 | Shareholders' equity / shares outstanding (diluted weighted shares when not reported). |
| Tangible book per share | -$9.90 | Tangible book value / shares outstanding. |
| Cash per share | $3.14 | (Cash + short-term investments) / shares outstanding. |
Valuation
| Metric | Value | How it is calculated |
|---|---|---|
| Market cap | $45.31B | Share price x shares outstanding. |
| Enterprise value | $46.15B | Market cap + total debt - cash - short-term investments. |
| P/E | 64.2x | Market cap / net income. Only when net income is positive. |
| P/S | 3.21x | Market cap / revenue. |
| P/B | 5.84x | Market cap / shareholders' equity. Only when equity is positive. |
| P/FCF | 33.6x | Market cap / free cash flow. Only when free cash flow is positive. |
| P/OCF | 23.9x | Market cap / cash from operations, when positive. |
| EV/Sales | 3.27x | Enterprise value / revenue. |
| EV/EBIT | 28.8x | Enterprise value / operating income, when both are positive. |
| EV/EBITDA | 17.8x | Enterprise value / EBITDA, when both are positive. |
| EV/FCF | 34.2x | Enterprise value / free cash flow, when both are positive. |
| FCF yield | 3.0% | Free cash flow / market cap. |
| Earnings yield | 1.6% | Net income / market cap (the inverse of P/E). |
What was TEVA PHARMACEUTICAL INDUSTRIES LTD's revenue in fiscal 2025?
TEVA PHARMACEUTICAL INDUSTRIES LTD reported revenue of $17.26B for fiscal 2025, 4.3% higher than the year before.
Was TEVA PHARMACEUTICAL INDUSTRIES LTD profitable in fiscal 2025?
Yes. Net income was $1.41B, a net margin of 8.2%.
How much free cash flow did TEVA PHARMACEUTICAL INDUSTRIES LTD generate in fiscal 2025?
Cash from operations of $1.65B minus capital expenditures of $501.0M left free cash flow of $1.15B.